About Trinity Biotech plc
https://www.trinitybiotech.comTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
CEO
John Gillard
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-27 | Reverse | 1:5 |
| 2024-02-23 | Reverse | 1:5 |
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:1.79M
Value:$1.25M
JANUS HENDERSON INVESTORS US LLC
Shares:1.42M
Value:$992.69K
HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC
Shares:487.11K
Value:$340.98K
Summary
Showing Top 3 of 46
About Trinity Biotech plc
https://www.trinitybiotech.comTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $10.97M ▲ | $7.37M ▲ | $-6.04M ▲ | -55.09% ▲ | $-0.32 ▲ | $-2.93M ▲ |
| Q1-2025 | $7.58M ▼ | $6.3M ▼ | $-8.8M ▲ | -116.21% ▼ | $-0.48 ▲ | $-5.85M ▲ |
| Q4-2024 | $15.86M ▲ | $16.39M ▲ | $-16.96M ▼ | -106.93% ▼ | $-1.2 ▼ | $-9.6M ▼ |
| Q3-2024 | $15.15M ▼ | $7.87M ▼ | $-4.76M ▲ | -31.41% ▲ | $-0.46 ▲ | $-1.11M ▲ |
| Q2-2024 | $15.84M | $9.79M | $-6.76M | -42.65% | $-0.71 | $-3.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $1.55M ▼ | $99.63M ▼ | $149.17M ▲ | $-49.54M ▼ |
| Q1-2025 | $4.07M ▼ | $99.79M ▼ | $143.41M ▲ | $-43.63M ▼ |
| Q4-2024 | $5.17M ▲ | $103.29M ▲ | $138.47M ▲ | $-35.18M ▼ |
| Q3-2024 | $2.84M ▼ | $97.45M ▲ | $123.79M ▲ | $-26.34M ▲ |
| Q2-2024 | $5.32M | $94.36M | $123.75M | $-29.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-6.04M ▲ | $-1.67M ▲ | $-2M ▼ | $1.09M ▼ | $-2.52M ▼ | $-1.71M ▲ |
| Q1-2025 | $-8.8M ▲ | $-2.96M ▼ | $-1.98M ▲ | $3.81M ▲ | $-1.1M ▼ | $-3.02M ▼ |
| Q4-2024 | $-16.96M ▼ | $3.35M ▲ | $-2.74M ▲ | $1.81M ▼ | $2.33M ▲ | $615K ▲ |
| Q3-2024 | $-4.76M ▲ | $-3.62M ▼ | $-3.1M ▲ | $4.24M ▲ | $-2.48M ▼ | $-6.32M ▼ |
| Q2-2024 | $-6.76M | $-1.1M | $-3.17M | $3.92M | $-459K | $-4.27M |
Revenue by Products
| Product | Q2-2022 |
|---|---|
 Clinical Laboratory | $30.00M ▲ |
 Laboratory Services | $0 ▲ |
CEO
John Gillard
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-08-27 | Reverse | 1:5 |
| 2024-02-23 | Reverse | 1:5 |
Ratings Snapshot
Rating : C
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:1.79M
Value:$1.25M
JANUS HENDERSON INVESTORS US LLC
Shares:1.42M
Value:$992.69K
HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC
Shares:487.11K
Value:$340.98K
Summary
Showing Top 3 of 46